go to contents

Vivaldi Biosciences AG

Back to list

Facts

Founded
2014
Staff
3
Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health

Profile

Vivaldi Biosciences is developing its DeltaFLU influenza vaccine to provide broad cross-protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1.

R&D:Administered as a nasal spray, DeltaFLU generates a first line of defense at the point of entry of circulating viruses. In clinical trials, DeltaFLU has been shown to induce antibodies in the nasal mucosa that cross-neutralize influenza strains of different subtypes. DeltaFLU strains are replication-deficient in animals and humans and are not shed by the recipient, providing significant safety advantages.

Similar companies in RDM biotech/pharma

ENSEMO GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Details

ViruSure GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

BlueSky Immunotherapies GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health / animal health
Details

Pharmonta Dr. Fischer GmbH

Organization type
RDM biotech/pharma
Region
Styria
Focus
human health
Details

Contact

Mariahilferstraße 101/1/21
1060 Wien
Vienna

Contact: Thomas Muster (Managing Director)
Email: thomas.muster@vivaldibiosciences.com
Website